<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:doc-ZAOMRABU</identifier><date>2010</date><creator>Hočevar, Marko</creator><relation>documents/doc/Z/URN_NBN_SI_doc-ZAOMRABU_001.pdf</relation><relation>documents/doc/Z/URN_NBN_SI_doc-ZAOMRABU_001.txt</relation><format format_type="volume">14</format><format format_type="issue">2</format><format format_type="type">article</format><format format_type="extent">str. 123-125, 168</format><identifier identifier_type="COBISSID">1046907</identifier><identifier identifier_type="ISSN">1408-1741</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-ZAOMRABU</identifier><language>slv</language><publisher>Onkološki inštitut Ljubljana</publisher><source>Onkologija (Ljubljana)</source><rights>BY</rights><subject language_type_id="eng">Antineoplastic agents</subject><subject language_type_id="eng">Drug therapy</subject><subject language_type_id="slv">ekstremitete</subject><subject language_type_id="eng">Extremities</subject><subject language_type_id="eng">Melanoma</subject><subject language_type_id="eng">Perfusion, regional</subject><subject language_type_id="slv">rak (medicina)</subject><subject language_type_id="eng">therapy</subject><subject language_type_id="slv">zdravljenje</subject><title>Izolirana ekstremitetna perfuzija</title></Record>